Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients. A Phase I Trial of the German Rectal Cancer Study Group
Latest Information Update: 06 Dec 2023
Price :
$35 *
At a glance
- Drugs Anakinra (Primary) ; Capecitabine (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Adverse reactions
- Acronyms ACO/ARO/AIO-21
- 28 Nov 2023 Planned End Date changed from 1 Jul 2026 to 31 Dec 2025.
- 28 Nov 2023 Planned primary completion date changed from 30 Sep 2025 to 31 Dec 2024.
- 28 Nov 2023 Status changed from recruiting to active, no longer recruiting.